Daily Cardiology Research Analysis
Three impactful cardiology studies span prevention, mechanisms, and therapeutics: a 240,346-participant UK Biobank cohort shows that higher Life’s Essential 8 scores markedly slow progression to cardiometabolic multimorbidity and death; an Advanced Science mechanistic study identifies MCPIP1 as a regulator of macrophage ferroptosis and heart–spleen communication after myocardial infarction; and a JACC Heart Failure analysis finds aficamten alone suffices for symptomatic obstructive HCM, enabling
Summary
Three impactful cardiology studies span prevention, mechanisms, and therapeutics: a 240,346-participant UK Biobank cohort shows that higher Life’s Essential 8 scores markedly slow progression to cardiometabolic multimorbidity and death; an Advanced Science mechanistic study identifies MCPIP1 as a regulator of macrophage ferroptosis and heart–spleen communication after myocardial infarction; and a JACC Heart Failure analysis finds aficamten alone suffices for symptomatic obstructive HCM, enabling disopyramide discontinuation without loss of efficacy.
Research Themes
- Cardiometabolic prevention using Life’s Essential 8
- Macrophage ferroptosis and heart–spleen axis in post-MI remodeling
- Therapeutic optimization in obstructive hypertrophic cardiomyopathy
Selected Articles
1. The Role of MCPIP1 in Macrophage Polarization and Cardiac Function Post-Myocardial Infarction.
In myeloid MCPIP1-deficient mice, MI outcomes were markedly worse (lower survival, larger infarcts, heightened inflammation) due to enhanced M1 polarization and impaired M2 transition linked to ferroptosis activation. Pharmacologic ferroptosis inhibition restored M2 polarization and reparative fibroblast activation, while splenectomy improved survival, implicating excessive splenic macrophage output. Mechanistically, MCPIP1 suppresses p53/ferroptosis and tunes TGF-β/SMAD3 signaling during cardiac repair.
Impact: This mechanistic work identifies MCPIP1 as a central regulator linking macrophage ferroptosis to post-MI inflammation and highlights a heart–spleen axis amenable to intervention.
Clinical Implications: While preclinical, the data nominate MCPIP1 and ferroptosis pathways as therapeutic targets to improve post-MI healing and suggest splenic modulation as a novel strategy. Biomarker development for macrophage ferroptosis could aid risk stratification.
Key Findings
- Myeloid MCPIP1 deficiency worsened MI outcomes with larger infarcts, lower survival, and heightened inflammation.
- Ferroptosis inhibitors (Fer-1, PFT-α) promoted M2 polarization and reparative fibroblast activation.
- Splenectomy improved survival and reduced infarct size in MCPIP1-deficient MI mice, implicating excessive extramedullary hematopoiesis.
- MCPIP1 suppressed the p53/ferroptosis pathway and modulated TGF-β/SMAD3 signaling during cardiac repair.
Methodological Strengths
- Multi-modal validation (histology, RNA-seq, co-culture, Western blot) across in vivo and in vitro systems
- Mechanistic perturbations including ferroptosis inhibitors and splenectomy to test causality
Limitations
- Preclinical mouse model; lack of human validation
- Specificity and safety of targeting MCPIP1/ferroptosis in the heart remain untested clinically
Future Directions: Develop selective MCPIP1/ferroptosis modulators; validate macrophage ferroptosis biomarkers in human MI; test efficacy in large-animal MI models and early-phase clinical trials.
Macrophages play a critical role in both initiating and resolving inflammation following MI (myocardial infarction). Their polarization is essential for maintaining cardiac function. This study aims to explore the role of MCPIP1(Monocyte chemotactic protein-induced protein 1) in regulating macrophage polarization and its impact on heart-spleen interactions during MI recovery. The role of MCPIP1 was investigated using histological staining, RNA sequencing of bone marrow-derived macrophages, co-culture experiments, and vali
2. Life's Essential 8 and progression of cardiometabolic multimorbidity trajectory: a prospective study of UK Biobank.
In 240,346 UK Biobank participants without baseline cardiometabolic disease, higher LE8 cardiovascular health scores were associated with markedly lower risks of transitioning from health to first cardiometabolic disease (HR 0.22), from first disease to cardiometabolic multimorbidity (HR 0.41), and to death. Benefits were consistent across disease-specific trajectories, underscoring LE8 as a powerful prevention framework.
Impact: This very large, long-term cohort provides rigorous, trajectory-based evidence that comprehensive cardiovascular health behaviors and factors (LE8) substantially mitigate cardiometabolic disease progression and mortality.
Clinical Implications: Clinicians can use LE8 as a practical target (≥80) to slow or prevent progression to multimorbidity and death, informing personalized prevention and population health strategies.
Key Findings
- High LE8 scores were associated with lower transitions from health to first cardiometabolic disease (HR 0.22; 95% CI 0.20–0.23) and to death (HR 0.23; 95% CI 0.21–0.25).
- From first cardiometabolic disease to multimorbidity, high LE8 was associated with HR 0.41 (95% CI 0.34–0.50).
- Benefits were consistent across disease-specific transitions, with some exceptions (e.g., from stroke and T2D to death).
Methodological Strengths
- Very large sample size (N=240,346) with median 14-year follow-up
- Use of multi-state models capturing full disease trajectories with adjustment for confounders
Limitations
- Observational design limits causal inference and residual confounding cannot be excluded
- UK Biobank volunteer bias may limit generalizability
Future Directions: Interventional trials targeting LE8 components to test causal effects on cardiometabolic trajectory; deployment in diverse populations to assess generalizability and implementation.
AIMS: To evaluate the impact of Life's Essential 8 (LE8) on the onset and progression trajectory of cardiometabolic multimorbidity (CMM). METHODS AND RESULTS: This prospective study included 240,346 participants (median age, 57 years) free of CMDs at baseline from the UK Biobank. LE8 scores were divided into low, moderate, and high cardiovascular health (CVH) groups at baseline, with higher LE8 scores representing better CVH. CMM was defined as the coexistence of two or three cardiometabolic diseases, including type
3. Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy.
Across three trials (50 unique patients; 93 segments), adding aficamten to disopyramide reduced LVOT gradients and symptoms, while aficamten withdrawal reversed benefits. Critically, disopyramide withdrawal while on aficamten did not diminish efficacy. Combination therapy was well tolerated but provided no additive clinical benefit beyond aficamten alone.
Impact: These results directly inform therapy optimization in symptomatic oHCM, supporting aficamten monotherapy and de-escalation of disopyramide without compromising efficacy.
Clinical Implications: For symptomatic oHCM with persistent LVOT obstruction, aficamten can be used without disopyramide; deprescribing disopyramide may simplify regimens and reduce anticholinergic burden, pending individualized evaluation.
Key Findings
- Aficamten add-on significantly reduced resting and Valsalva LVOT gradients (LS mean changes −27.0 and −39.2 mmHg; both P<0.0001) and improved symptoms (≥1 NYHA class improvement in 77.8%).
- Withdrawing aficamten while on disopyramide reversed improvements; withdrawing disopyramide while on aficamten did not diminish efficacy.
- No safety signals with combination or withdrawal; no atrial fibrillation episodes after disopyramide withdrawal.
Methodological Strengths
- Aggregated data from three clinical trials including a placebo-controlled study
- Objective hemodynamic endpoints and standardized assessments across segments
Limitations
- Nonrandomized allocation to withdrawal sequences; modest sample size
- Short follow-up; generalizability to broader oHCM populations requires confirmation
Future Directions: Randomized withdrawal trials to confirm deprescribing strategies; longer-term outcomes (arrhythmias, remodeling) and quality-of-life with aficamten monotherapy.
BACKGROUND: Disopyramide, used in obstructive hypertrophic cardiomyopathy (oHCM) for its negative inotropic properties mediated by its reduction in cytosolic calcium, has been recommended for decades as an option to relieve resistant obstruction. Aficamten is a selective cardiac myosin inhibitor that reduces hypercontractility directly by reducing myosin-actin interaction. OBJECTIVES: This study aims to investigate the safety and efficacy of concomitant use and withdrawal of disopyramide in patients with symptomatic oHCM receivi